Search results
Showing 91 to 105 of 112 results for bladder cancer
Interventional procedures, IPG235 - Issued: October 2007 --> This guidance has been updated and replaced by NICE interventional procedures guidance 628.
Electrically stimulated intravesical chemotherapy for non-muscle-invasive bladder cancer (IPG638)
We have moved interventional procedures guidance 638 to become HealthTech guidance 499. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.
Transurethral laser ablation for recurrent non-muscle-invasive bladder cancer (IPG656)
We have moved interventional procedures guidance 656 to become HealthTech guidance 522. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.
Durvalumab for untreated PD-L1 positive metastatic urothelial bladder cancer [ID1169]
Discontinued Reference number: GID-TA10324
Intravesical microwave hyperthermia and chemotherapy for non-muscle-invasive bladder cancer (IPG628)
We have moved interventional procedures guidance 628 to become HealthTech guidance 487. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.
Durvalumab with tremelimumab for untreated PD-L1-positive urothelial bladder cancer [ID1335]
Discontinued Reference number: GID-TA10315
This guideline covers the routine postnatal care that women and their babies should receive in the first 8 weeks after the birth. It includes the organisation and delivery of postnatal care, identifying and managing common and serious health problems in women and their babies, how to help parents form strong relationships with their babies, and baby feeding. The recommendations on emotional attachment and baby feeding also cover the antenatal period.
In development Reference number: GID-TA11556 Expected publication date: TBC
In development Reference number: GID-TA11884 Expected publication date: TBC
Evidence-based recommendations on selumetinib (Koselugo) for treating symptomatic and inoperable plexiform neurofibromas associated with type 1 neurofibromatosis in children aged 3 and over.
KRAS mutation testing of tumours in adults with metastatic colorectal cancer (discontinued)
Discontinued Reference number: GID-DT14
In development Reference number: GID-TA11654 Expected publication date: TBC
This guideline covers identifying and managing menopause, including in people with premature ovarian insufficiency. It aims to improve the consistency of support and information provided to people experiencing menopause.
Faecal calprotectin diagnostic tests for inflammatory diseases of the bowel (HTG320)
Evidence-based recommendations on faecal calprotectin tests for distinguishing between inflammatory bowel diseases (such as Crohn’s disease and ulcerative colitis) and non-inflammatory bowel diseases (such as irritable bowel syndrome).
This guideline covers the planning and management of end of life and palliative care for infants, children and young people (aged 0 to 17 years) with life-limiting conditions. It aims to involve children, young people and their families in decisions about their care, and improve the support that is available to them throughout their lives.